+

NO20066056L - Behandling med Gemcitabin og en EGFR-inhibitor - Google Patents

Behandling med Gemcitabin og en EGFR-inhibitor

Info

Publication number
NO20066056L
NO20066056L NO20066056A NO20066056A NO20066056L NO 20066056 L NO20066056 L NO 20066056L NO 20066056 A NO20066056 A NO 20066056A NO 20066056 A NO20066056 A NO 20066056A NO 20066056 L NO20066056 L NO 20066056L
Authority
NO
Norway
Prior art keywords
gemcitabine
kinase inhibitor
treatment
egfr kinase
egfr inhibitor
Prior art date
Application number
NO20066056A
Other languages
English (en)
Inventor
Brian Higgins
Kenneth Kolinsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20066056L publication Critical patent/NO20066056L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for fremstilling av et medikament for behandling av tumorer eller tumormetastaser, kjennetegnet ved at det anvendes en terapeutisk effektiv mengde av en EGFR-kinaseinhibitor og gemcitabin, med eller uten ytterligere midler eller behandlinger, så som andre antikreftmedikamenter eller strålingsterapi. Oppfinnelsen omfatter også et farmasøytisk preparat som består av en EGFR-kinaseinhibitor- og gemcitabinkombinasjon i kombinasjon med en farmasøytisk akseptabel bærer. Et foretrukket eksempel på en EGFR-kinaseinhibitor som kan anvendes ved utøvelse av denne oppfinnelse, er forbindelsen eriotinib-HCI (også kjent som Tarceva TM).
NO20066056A 2004-06-03 2006-12-28 Behandling med Gemcitabin og en EGFR-inhibitor NO20066056L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57654104P 2004-06-03 2004-06-03
PCT/EP2005/005735 WO2005117887A1 (en) 2004-06-03 2005-05-27 Treatment with gemcitabine and an egfr-inhibitor

Publications (1)

Publication Number Publication Date
NO20066056L true NO20066056L (no) 2007-01-25

Family

ID=34970803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066056A NO20066056L (no) 2004-06-03 2006-12-28 Behandling med Gemcitabin og en EGFR-inhibitor

Country Status (15)

Country Link
US (1) US20050272688A1 (no)
EP (1) EP1755608A1 (no)
JP (1) JP2008501652A (no)
KR (1) KR100986945B1 (no)
CN (1) CN1960732A (no)
AU (1) AU2005249205A1 (no)
BR (1) BRPI0511760A (no)
CA (1) CA2567836A1 (no)
IL (1) IL179525A0 (no)
MX (1) MXPA06014015A (no)
NO (1) NO20066056L (no)
NZ (1) NZ551406A (no)
RU (1) RU2006146619A (no)
WO (1) WO2005117887A1 (no)
ZA (1) ZA200610049B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
JP2008501651A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー イリノテカン（ｃｐｔ−１１）およびｅｇｆｒ阻害剤を用いた処置
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
KR101625347B1 (ko) * 2005-02-18 2016-05-27 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
US7651687B2 (en) * 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
US20090209580A1 (en) * 2006-05-18 2009-08-20 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2007146226A2 (en) * 2006-06-09 2007-12-21 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
AU2008205847A1 (en) * 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
MX2010002081A (es) * 2007-08-23 2010-06-01 Plus Chemicals Sa Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
US8436044B2 (en) 2008-01-28 2013-05-07 Nanocarrier Co., Ltd. Pharmaceutical composition or combination drug
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
US20120149647A1 (en) * 2009-03-17 2012-06-14 Brody Jonathan R Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels
CA2713610C (en) * 2009-10-02 2019-08-20 Monash University Ectopic pregnancy treatment
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
CL2011000273A1 (es) 2011-02-08 2011-06-17 Univ Pontificia Catolica Chile Uso de un inhibidor de la enzima fosfohidrolasa de acido fosfatidico (pap) o combinacion de inhibidores, en que el inhibidor es d(+) propranolol, y la combinacion es mezcla racemica de propranolol o d(+) propranolol junto con desipramina, para preparar un medicamento util en el tratamiento del cancer.
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013006230A2 (en) * 2011-07-01 2013-01-10 Fox Chase Cancer Center Combined inhibition of the vitamin d receptor and dna replication in the treatment of cancer
CA2858246C (en) 2011-11-04 2019-11-12 Paul Zachary JOSEFOWITZ Use of neu1 sialidase inhibitors in the treatment of cancer
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2015166986A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
US9889141B2 (en) 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
EP3338779B1 (en) 2015-08-20 2021-06-30 Eisai R&D Management Co., Ltd. Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
RU2019140001A (ru) * 2017-05-18 2021-06-18 Ту Ту Биотек Лтд. Способ сенсибилизации раковых клеток к противораковой терапии
AU2019288048B2 (en) 2018-06-20 2022-08-11 Fujifilm Corporation Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
AU782994C (en) * 1999-05-14 2006-08-24 Imclone Llc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7344829B2 (en) * 2000-11-03 2008-03-18 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
US20020076408A1 (en) * 2000-12-08 2002-06-20 Buchsbaum Donald J. Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer

Also Published As

Publication number Publication date
NZ551406A (en) 2010-03-26
ZA200610049B (en) 2008-06-25
CA2567836A1 (en) 2005-12-15
WO2005117887A1 (en) 2005-12-15
JP2008501652A (ja) 2008-01-24
KR20070029736A (ko) 2007-03-14
AU2005249205A1 (en) 2005-12-15
CN1960732A (zh) 2007-05-09
BRPI0511760A (pt) 2008-01-08
MXPA06014015A (es) 2007-02-08
RU2006146619A (ru) 2008-07-20
KR100986945B1 (ko) 2010-10-12
EP1755608A1 (en) 2007-02-28
IL179525A0 (en) 2007-07-04
US20050272688A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
Singh et al. Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CR20220558A (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
EA202190630A1 (ru) Способы комбинированной терапии
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
WO2006110175A3 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20092604L (no) VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament.
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
JP2018508593A5 (no)
NO20066057L (no) Behandling med oksaliplatin og en EGFR-inhibitor
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载